KPV is a well-researched peptide used for overall gut health and has shown effectiveness for the treatment of inflammatory bowel disease (IBD). Its anti-inflammatory properties make KPV also helpful with skin conditions such as psoriasis.
KPV is a naturally occurring tripeptide composed of the amino acids Lysine, Proline and Valine. It has been shown to reduce the inflammatory responses of colonic cells. It has also been shown to be nontoxic and biocompatible with intestinal cells, acting inside of the cell.
The current standard treatment for ulcerative colitis is the use of immunosuppressive drugs to control the inflammation of the gastrointestinal tract. Unfortunately, these drugs are associated with serious adverse side effects including the promotion of osteoporosis and an increased susceptibility to infection.5, 6 There is a great need for nontoxic treatments for this condition.
Ulcerative colitis (UC) is a chronic, relapsing inflammatory disease of the colon. 1 The inflammatory response of the lining of the colon damages the colonic mucosal barrier, which causes an increased permeability of epithelial barrier and increases the risk of bacterial invasion into colonic tissues. An excessive immune reaction is believed to induce the symptoms of ulcerative colitis- primarily diarrhea associated with bleeding 2 The goal in treatment for ulcerative colitis is to promote mucosal healing and alleviate inflammation and its consequences .3, 4
Studies have shown that KPV can ameliorate the inflammatory response of the lining of the colon- the epithelial (outer lining) – and immune cells which may reduce the incidence of ulcerative colitis flareups.11, 12 The science has shown that KPV exerts its anti-inflammatory function inside the cells, where it inactivates the problematic out of control inflammatory pathways.12 And unlike the drugs currently used for Ulcerative colitis, KPV is a naturally derived tripeptide. The mechanism by which KVP acts as an anti-inflammatory treatment are not well understood. Studies indicate that KPV inhibits the activation of NF-kappaB and MAP kinase inflammatory signaling pathways. This will reduce secretion of pro-inflammatory cytokines. It has been shown to act without the risk of any significant side effects.
https://pubmed.ncbi.nlm.nih.gov/18061177/
Enhancement of mucosal healing is one of the two major aims in Ulcerative Colitis treatment.18 Because KPV was shown to decrease the inflammatory response of colonic epithelial cells to inflammatory stimulation,12 it is reasonable to speculate that KPV might improve the healing of the underlying inflamed mucosal layer as well. This effects of KPV on wound healing was studied by using electrical impedance sensing (ECIS) technology. The results showed Figure 4, that wounded epithelial layers treated with KPV demonstrate healing of injured colonic tissues.
httpsps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498804/
Together, these results show that KPV reduces NF-κB and MAPK activation which constitute the classical signaling pathways involved in cytokine secretion by inflamed IEC.
Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease.
The fact that KPV acts locally after oral ingestion makes it a n excellent candidate for effective treatment.
https://pubmed.ncbi.nlm.nih.gov/23036075/
Since IBD (Inflammatory Bowel Disease) is chronic and relapsing, patients are generally placed on a regimen of lifelong medication. The immunosuppressive agents used to treat the condition have significant adverse effects. Oral colon-specific agents are used to deliver the therapeutic effect locally and target pathophysiological inflammatory manifestations of Inflammatory Bowel Disease. KPV can be taken orally and be active in the colon after it is ingested. It has not been associated with any significant negative side effects.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2431115/
MAXIMIZING THERAPY USING KPV TOGETHER WITH BPC -157
Another well studied peptide treatment for intestinal tissues is Body Protective Compound known as BPC. It is a fifteen amino acid peptide originally derived from gastric juice secretions.
https://drsobo.com/peptides/bpc-157/
BPC-157 is used to treat many common gastrointestinal disorders. It is able to be given as an orally because it is stable in gastric juice after ingestion. It benefits stem from helping optimal functioning of the gut-brain axis-the connection between the gastrointestinal tract, and the nervous system.
BPC-157 is used to treat
- Crohn’s disease
- Ulcerative colitis
- Leaky gut syndrome
- Constipation or diarrhea
- Ulcers
- Chronic constipation or diarrhea
Both KPV and BPC-157 can be given together to enhance the therapeutic effect for a more complete healing treatment to combat IBD (Inflammatory Bowel Disease.
TREATING THE MICROBIOME IN INFLAMMATORY BOWEL DISEASE
To add another helpful nontoxic approach to these disorders, ongoing studies show us that improving the state of the bacterial environment of the colon may be extremely helpful:
- The gut microbiome is different in IBD patients. One study elucidating this showed that the variety of common bacteria and other microorganisms in the gastrointestinal tract is different in IBD when compared to healthy individuals. The study was published in the Journal of Experimental Medicine.
Dr. Marcel de Zoete, published a paper in the International Journal of Systematic and Evolutionary Microbiology, showing that those with IBD have different bacterial species in their intestinal tracts. This research may offer new insights into the underlying mechanisms involved in IBD, and may point toward new ideas for safe, nontoxic treatments.
- Other research has studied immune cells in the intestine’s tract and their communication with cells of the intestinal lining and microbes lining the gut. A layer of Intestinal epithelial cells which make up the inner lining of the gut and act as a first line of defense against microbes-these.
- Intestinal lymphocytes Trusted Source communicate with Intestinal epithelial cells to promote tissue repair and intestinal homeostasis.
Ulcerative Colitis and Crohn’s Disease are the two conditions encompassed by the term IBD-Inflammatory Bowel Disease. Safe, nontoxic treatments need to be further studied and developed.
